Pieris Pharmaceuticals Inc

NASDAQ:PIRSUnited States

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline includes an inhaled IL-4Rα antagonist Anticalin protein to treat asthma, an immuno-oncology (IO), bispecific targeting HER2 and 4-1BB, and an IO bispecific targeting PD-L1 and 4-1BB. Its lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, which are small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein.

Contact Information

Headquarters

225 Franklin Street, 26Th FloorBOSTON, MA, United States 02110

Phone

857-246-8998

Fax

---

Executives

Independent Director

James Geraghty

President, Chief Executive Officer, Director

Stephen Yoder

Chief Financial Officer, Senior Vice President

Thomas Bures

Senior Vice President, Chief Scientific Officer

Hitto Kaufmann

Senior Vice President, Chief Business Officer, General Counsel, Company Secretary

Ahmed Mousa